Assil Eye Institute — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$98,720	4
2021	Research	$21,353	4
2020	Research	$23,005	3
2019	Research	$9,552	5

Breakdown

Who paid Research payments · program years 2019–2022

Ocular Therapeutix, Inc. $132,780 7 payments
Sight Sciences, Inc. $8,600 2 payments
Glaukos Corporation $7,398 6 payments
Allergan Inc. $3,852 1 payment

Studies the money was for Research payments · program years 2019–2022

A Randomized controlled clinical trial aSsessing the efficacy of DEXTENZA, Sustained release dexamethasone 0.4 mg Insert when placed within the upper eye lid canaliculus in comparison to the lower lid canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular Lens implant (CE/PCIOL) $80,780 4 payments
A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert In-Office Prior to or Following Cataract Surgery $30,000 1 payment
The ASSIL Study $22,000 2 payments
A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery $7,398 6 payments
A Prospective Multicenter Study of the OMNI Surgical System in Pseudophakic Eyes with Open Angle Glaucoma (ORION) $5,100 1 payment
Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $3,852 1 payment
A Retrospective Observational Multicenter 12-Month Follow-Up Study Of Patients With Open-Angle Glaucoma Treated With The Omni Surgical System As A Standalone Procedure In Pseudophakic Patients Or Combined With Cataract Surgery (ROMEO II) $3,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.